DOCSLIB.ORG

KKL-JNF Provides Outdoor Relaxation Areas for Hospitals in Israel

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
KKL-JNF Provides Outdoor Relaxation Areas for Hospitals in Israel Illustration: KKL-JNF Central Planning Division Green respite in the time of COVID-19: KKL-JNF Provides Outdoor Relaxation Areas for Hospitals in Israel "At this challenging time, KKL-JNF will create relaxation areas at Israel's hospitals to strengthen the morale of patients, medical staff and visitors, enabling them to take time for respite in open green environments." Daniel Atar, KKL-JNF World Chairman, August 2020 In light of the ongoing COVID-19 pandemic and the danger of infection in enclosed spaces, KKL-JNF is planning to establish a network of specially designed, green outdoor shaded seating areas for between 25 to 30 hospitals that have coronavirus wards throughout Israel. The nationwide project will serve to strengthen and support the medical teams working around the clock and the COVID-19 patients, isolated from home and family, whose length of stay may be protracted. The project will be designed and used in accordance with the directives of the Ministry of Health. The benefits of spending time in a green environment in the open air are well known, enhancing well-being, health and recuperation. The seating areas will provide respite for all who need them, not least medical staff under unusual pressure, and serve as pleasant "green lungs" for hospitals. The plan to create outdoor seating areas took shape at the request of Prof. Ronni Gamzu, director of the Ichilov Medical Center and the national coronavirus project manager, and that of the Soroka Hospital in Be'er Sheva. In response to the expressed need, the KKL-JNF Board of Directors are planning the project's implementation at the Shaare Zedek Medical Center in Jerusalem, the Sheba Medical Center at Tel HaShomer in Ramat Gan, the Hillel Yaffe Medical Center in Hadera, the Padeh (Poriya) Medical Center near Tiberias, among others. Already, within the next year, the hospitals will have seating areas that include accessible KKL-JNF tables and benches spaced at a distance of at least two meters between them, newly planted shade trees and greenery, flower box planters, and shading elements (umbrellas). The designated areas will be KKL-JNF branded. Project cost: NIS 25,000 for each relaxation area Donors will receive appropriate recognition in the form of a plaque attached to a table or bench. List of hospitals where KKL-JNF's Relaxation Areas will be established 1. Ziv Medical Center – Safed (Tzfat) 13. Tel Aviv Sourasky Medical Center – Tel Aviv 2. Galilee Medical Center – Nahariya 14. Mayanei Hayeshua Medical Center – Bnei Brak 3. Padeh -Poriya Medical Center – Ramat Poriya 15. Hadassah Medical Center, Mount Scopus – Jerusalem 4. Rambam Health Care Campus – Haifa 16. Hadassah Medical Center, Ein Kerem – Jerusalem 5. Bnai Zion Medical Center – Haifa 17. Shaare Zedek Medical Center – Jerusalem 6. Carmel Medical Center – Haifa 18. Wolfson Medical Center – Holon 7. HaEmek Medical Center – Afula 19. Kaplan Medical Center – Rehovot 8. Hillel Yaffe Medical Center – Hadera 20. Yitzhak Shamir Medical Center – Be'er Ya'akov 9. Laniado Hospital – Netanya 21. Assuta Ashdod Medical Center – Ashdod 10. Meir Medical Center – Kfar Saba 22. Barzilai Medical Center – Ashkelon 11. Rabin Medical Center – Petah Tikva 23. Soroka Medical Center – Be'er Sheva 12. Sheba Medical Center at Tel HaShomer – Ramat Gan 24. Yoseftal Medical Center – Eilat Take Part and Make Your Mark! We would be delighted to have you partner with us in this meaningful project for the future of Israel • Photos for illustrative purposes only. • The information contained herein is not legally binding. קרן קימת לישראל Keren Kayemeth LeIsrael Jewish National Fund Global Resource Development Division Marketing Department Jerusalem 2020 .
Load more

Recommended publications
  • Scientific Program
    www.iscort.org.il Scientific Program 08.01.2019 - 12.01.2019, Eilat, Israel The Annual Meeting of The Israeli Society for Clinical Oncology and Radiation Therapy ISCORT wishes to express its gratitude to the following companies הוועדה המארגנת for their support of the 19th ISCORT Annual Meeting: Organizing Committee ISCORT 19 נשיא הכנס: :President פרופ׳ סלומון שטמר Platinum Sponsor Salomon M. Stemmer, MD Roche מזכירת הכנס: :Secretory ד״ר ולריה סמניסטי Gold Sponsor Valeria Semenysty, MD יו"ר הרדיותרפיה: :BMS Radiation Oncology Co-Chair פרופ׳ בן קורן MSD Ben W. Corn, MD הוועדה המדעית Silver Sponsor Scientific Committee ISCORT 19 Astellas יו"ר: פרופ׳ מיכל לוטם Astrazeneca Chairman: Michal Lotem, MD ד"ר אהרון אלון Boehringer Ingelheim Aaron Allen, MD ד"ר נועם אסנה Eli Lilly Noam Asna, MD ד"ר יאיר בר ISI Jair Bar, MD PhD ד"ר יהונתן כהן Novartis Yonathan Cohen, MD PhD פרופ׳ בן קורן Pfizer Ben W. Corn, MD ד"ר אלה עברון Rafa Ella Evron, MD ד"ר דניאלה כץ Daniela Katz, MD פרופ׳ גל מרקל Bronze Sponsor Gal Markel, MD PhD ד"ר אינה אוספובט AbbVie Inna Ospovat, MD ד"ר אביבית פאר Assuta Avivit Peer, MD ד"ר רות פרץ Bayer Ruth Perets, MD PhD Bolpharma ד"ר רפאל פפר Raphael Pfeffer, MD Dexcel Pharma ד"ר קרן רובינוב Keren Rouvinov, MD Isotopia ד"ר יקטרינה שולמן Katerina Shulman, MD Medison ד"ר אמיר זוננבליק Merck Amir Sonnenblick, MD ד"ר מרק ויגודה Nanostring Marc Wygoda, MD ד"ר אלונה זר Neopharm Alona Zer, MD ד"ר אביעד זיק Oncotest-Teva Aviad Zik, MD Perrigo החברה המארגנת Sanofi Organizing Company א.מ.
    [Show full text]
  • Israel Endocrine Society
    Israel Endocrine Society Israel Endocrine Society Conference Browse the program for the upcoming event By Session All Sessions By ID 4 By Day Tuesday By Author Aizic, A. - 31 Now Viewing: All Sessions Note: The presenter's name is in bold Registration Tuesday Morning Date: Tuesday, April 9, 2013 Time: 7:30 AM - 8:00 AM Location: Oral Presentations I: Diabetes, Obesity and Metabolism Date: Tuesday, April 9, 2013 Time: 8:00 AM - 10:00 AM Location: Bareket Hall Session Chair: Benjamin Glaser Session Chair: Hannah Kanety 8:00 AM - AMPK corrects ER morphology and function in stressed pancreatic beta-cells via regulation of the ER resident protein DRP1 (ID: 25) Jakob Wikstrom (Israel) Tal Israeli (Israel) Etty Bachar-Wikstrom (Israel) Yafa Ariav (Israel) Erol Cerasi (Israel) Gil Leibowitz (Israel) 8:15 AM - Paradox In Metabolic Homeostasis: AHNAK Knockout Mice Are Resistant To Diet-Induced Obesity And Yet They Display Reduced Insulin Sensitivity (ID: 47) Maya Ramdas (Israel) Chava Harel (Israel) Natalia Krits (Israel) http://www.xcdsystem.com/ies2013/Program/index.cfm[05/04/2013 11:15:55] Israel Endocrine Society Michal Armoni, Rambam Medical Center (Israel) Eddy Karnieli, Institute of Endocrinology, Metabolism and Diabetes (Israel) 8:30 AM - Neonatal Wolfram syndrome: novel De-novo dominant mutation presenting as an unusual clinical phenotype (ID: 52) Abdulsalam Abu-Libdeh, Hadassah Hebrew University Hospital (Israel) 8:45 AM - Importance of maintaining redox potential balance in the development of type 2 diabetes (ID: 61) Tovit Rosenzweig,
    [Show full text]
  • The New Neonatal Care Center at Soroka Medical Center
    The New Neonatal Care Center at Soroka Medical Center 1 2 The New Neonatal Care Center at Soroka Medical Center The new Neonatal Care Center will serve all newborns in the Negev and provide full protection against missile attacks in accordance with the standards of the Home Front Command of the Israel Defense Forces. Soroka Medical Center: An Overview With 1,100 beds, Soroka Medical Center is among Israel’s largest and most advanced hospitals, and the country’s busiest. Soroka is the only major medical center in the entire Negev, serving a population of more than one million inhabitants, including 400,000 children, in a region that accounts for 60% of the country’s total land area. Soroka serves as the teaching hospital of both the Medical School of Ben-Gurion University, whose Faculty of Health Sciences is located on the hospital campus, and its Medical School for International Health. On par with leading international institutions, Soroka specializes in areas that include, for example, early detection and treatment of breast cancer using minimally invasive procedures; non-invasive removal of malignant tumors; trauma rehabilitation of children and adolescents; pediatric infectious diseases; and much more. Each year, excellent care is provided to more than 750,000 people at outpatient and clinic visits; 235,000 patients visit our Emergency Medicine Department (the busiest in the country); 80,000 inpatients fill our beds; over33 ,000 patients undergo surgery, and more than 17,000 babies are born. Soroka’s neonatal and pediatric departments provide family-centered intensive care with world-class survival rates. Soroka’s Trauma Unit is the largest and busiest in Israel, always on call, 24 hours a day, 365 days a year.
    [Show full text]
  • Recurrent Deep Venous Thrombosis in a Patient with Agenesis of Inferior Vena Cava
    International Journal of General Medicine Dovepress open access to scientific and medical research Open Access Full Text Article CASE REPORT Recurrent deep venous thrombosis in a patient with agenesis of inferior vena cava William Nseir1 Background: Agenesis of the inferior vena cava (IVC) as a cause of recurrent deep vein Mahmud Mahamid1 thrombosis (DVT) is uncommon. Zuhair Abu-Rahmeh2 Case: A 33-year-old male with no family history of thrombophilia, who had experienced mul- Arieh Markel3,4 tiple recurrent episodes of DVT over a 15-year period of unknown cause, was admitted into our hospital because of cellulitis in the right leg. Computer tomography with contrast of the 1Department of Internal Medicine, 2Radiology Department, Holy abdomen showed an absence of IVC. Family Hospital, Nazareth, Israel; Conclusion: Congenital absence of the IVC could be a rare risk factor for idiopathic DVT, 3 Department of Internal Medicine A, especially in young individuals. Haemek Medical Center, Afula, Israel; 4Technion, Faculty of Medicine, Haifa, Keywords: deep vein thrombosis, agenesis, inferior vena cava Israel Background Venous thromboembolism (VTE), which includes deep vein thrombosis (DVT) and pulmonary embolism, has an incidence of 1 to 3 per 1000 individuals per year in Western populations.1 Congenital anomalies of the inferior vena cava (IVC) are uncommon, and have been associated with the development of venous thrombosis of the lower limbs.2 Congenital anomalies of the IVC has been reported as a risk factor for DVT, especially in individuals ,30 years old, and a concomitant thrombophilic disorder has been found in such individuals.3 We report a case of recurrent DVT in a 33-year-old man with agenesis of the IVC.
    [Show full text]
  • The Right Atrium of Patients with Various Heart Diseases Retain Progenitor Cells with Regenerative Capacity
    S7 - Prognosis and Outcome in Heart Failure The Right Atrium of Patients with Various Heart Diseases Retain Progenitor Cells with Regenerative Capacity Ayelet Itzhaki-Alfia 1, Jonathan Leor 1,Shiri Netser1, Leonid Sternik 2, Dan Spiegelstein 2, David Mishaly 2, Jacob Lavee 2, Ehud Raanani 2,Barbash Israel M3 1 Neufeld Cardiac Research Institute, Sackler Faculty of Medicine,Tel-Aviv University, 2 Department of Cardiothoracic Surgery, 3 Neufeld Cardiac Research Institute, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel The 55th Annual Conference of the I.H.S and the I.S.C.S 37 S7 - Prognosis and Outcome in Heart Failure The Impact of the NT-proBNP Assay in the Emergency Department on the Diagnosis of Heart Failure and on Outcomes in Patients Admitted for Dyspnea: A Prospective Randomized Placebo-controlled Double-center Trial (BNP4EVER) Simcha Meisel 1, Margarita Medvedovski 2, Moshe Sharist 3, Jalal Ashkar 2,Pavel Pschianski2, Michael Glikson 4, Shmuel Bar Haim 3, Michael Shochat 1, David Blondheim 1, Avraham Shotan 1 1 Heart Institute, Hillel Yaffe Medical Center, 2 Emergency Department, Hillel Yaffe Medical Center, Hadera, 3 Emergency Department, Assaf Harofeh Medical Center, Zerifin, 4 Heart Institute, Chaim Sheba Medical Center, Hadera, Israel The 55th Annual Conference of the I.H.S and the I.S.C.S 38 S7 - Prognosis and Outcome in Heart Failure Echocardiographic and Plasma N-Terminal Pro-B Type Natriuretic Peptide Evaluation During Pregnancy in Patients with Preexisting Dilated Cardiomyopathy Alex Blatt 1,Ilya Litovchik1, Ricardo
    [Show full text]
  • Spotted Fever Group Rickettsioses in Israel, 2010–2019
    Spotted Fever Group Rickettsioses in Israel, 2010–2019 Regev Cohen, Talya Finn, Frida Babushkin, Yael Paran, Ronen Ben Ami, Alaa Atamna, Sharon Reisfeld, Gabriel Weber, Neta Petersiel, Hiba Zayyad, Eyal Leshem, Miriam Weinberger, Yasmin Maor, Nicola Makhoul, Lior Nesher, Galia Zaide, Dar Klein, Adi Beth-Din, Yafi t Atiya-Nasagi ≈ In a multicenter, nationwide, retrospective study of pa- SFGRs are associated with 20 species of Rickettsia, tients hospitalized with spotted fever group rickettsiosis of which 16 are considered human pathogens (1,2). in Israel during 2010–2019, we identifi ed 42 cases, of Recent introduction of molecular methods provided which 36 were autochthonous. The most prevalent spe- more information about SFGR agents causing human cies was the Rickettsia conorii Israeli tick typhus strain (n disease and enabled their identifi cation, for which = 33, 79%); infection with this species necessitated inten- the clinical signifi cance of some remains lacking (3). sive care for 52% of patients and was associated with a R. conorii complex, the etiologic agent of Mediterra- 30% fatality rate. A history of tick bite was rare, found for nean spotted fever, includes 4 strains: R. conorii Mal- only 5% of patients; eschar was found in 12%; and leuko- ish (cause of Mediterranean spotted fever), R. conorii cytosis was more common than leukopenia. Most (72%) Astrakhan (cause of Astrakhan fever), R. conorii In- patients resided along the Mediterranean shoreline. For 3 dian tick typhus (cause of Indian tick typhus), and R. patients, a new Rickettsia variant was identifi ed and had been acquired in eastern, mountainous parts of Israel.
    [Show full text]
  • Scientific Program
    The 63th Annual Conference of the Israel Heart Society in association with the Israel Society of Cardiothoracic Surgery April 12-13 • 2016 • Tel Aviv, Israel SCIENTIFIC PROGRAM Paragon Israel (Dan Knassim) Paragon Tel/Fax:03-5767730/7 Israel (Dan Knassim) a Paragon Group Company [email protected] TUESDAY, APRIL 12, 2016 08:30-10:00 Interventional Cardiology I Hall A Chairs: Ariel Finkelstein, Ran Kornowski, Israel 08:30 Effect of Diameter of Drug-Eluting Stents Versus Bare-Metal Stents on Late Outcomes: a propensity score-matched analysis Amos Levi1,2, Tamir Bental1,2, Hana Veknin Assa1,2, Gabriel Greenberg1,2, Eli Lev1,2, Ran Kornowski1,2, Abid Assali1,2 1Cardiology, Rabin Medical Center, Israel 2Sackler Faculty of Medicine, Tel Aviv University, Israel 08:41 Percutaneous Valve-in-Valve Implantation for the Treatment of Aortic, Mitral and Tricuspid Structural Bioprosthetic Valve Degeneration Uri Landes1, Abid Assali1, Ram Sharoni1,2, Hanna Vaknin-Assa1, Katia Orvin1, Amos Levi1, Yaron Shapira1, Shmuel Schwartzenberg1, Ashraf Hamdan1, Tamir Bental1, Alexander Sagie1, Ran Kornowski1 1Department of Cardiology, Rabin Medical Center, Tel Aviv, Israel 2Department of Cardiac Surgery, Rabin Medical Center, Tel Aviv, Israel 08:52 Temporal Trends in Transcatheter Aortic Valve Implantation in Israel 2008-2014: Patient Characteristics, Procedural Issues and Clinical Outcome Uri Landes1, Alon Barsheshet1, Abid Assali1, Hanna Vaknin-Assa1, Israel Barbash3, Victor Guetta3, Amit Segev3, Ariel Finkelstein2, Amir Halkin2, Jeremy Ben-Shoshan2,
    [Show full text]
  • Antibiotic Treatment for Invasive Listeriosis and Patient
    Antibiotic treatment for invasive listeriosis and patient outcome: a retrospective cohort study Yaakov Dickstein1, Yonatan Oster2, Orit Shimon3, Lior Nesher4, Dafna Yahav3,5, Yonit Wiener-Well6, Regev Cohen7,8, Ronen Ben-Ami3,9, Miriam Weinberger3,10, Galia Rahav3,11, Yasmin Maor3,12, Michal Chowers3,13, Ran Nir-Paz2, Mical Paul1,8 1 Institute of Infectious Diseases, Rambam Health Care Campus, Haifa, Israel 2 Department of Clinical Microbiology and Infectious Diseases, Hadassah-Hebrew University Medical Center, Jerusalem, Israel 3 Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel 4 Infectious Disease Institute, Soroka Medical Center, Ben-Gurion University of the Negev, Beer Sheba, Israel 5 Infectious Diseases Unit, Rabin Medical Center, Beilinson hospital, Petah-Tikva, Israel 6 Infectious Disease Unit, Shaare Zedek Medical Center, Jerusalem, Israel 7 Infectious Diseases Unit, Sanz Medical Center–Laniado Hospital , Netanya, Israel 8 The Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel 9 Infectious Diseases Unit, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel 10 Infectious Diseases Unit, Assaf Harofeh Medical Center, Zerifin, Israel 11 Infectious Disease Unit, Sheba Medical Center, Ramat Gan, Israel 12 Infectious Disease Unit, Wolfson Medical Center, Holon, Israel 13 Infectious Diseases Unit, Meir Medical Center, Kfar Saba, Israel Cumulative survival by treatment group Background: Current treatment started within 48 hours of culture recommendations for treatment of results and continued for a minimum duration invasive listeriosis suggest ampicillin- of 7 days. Patients who died within 48 hours of based therapy with the addition of an the index culture were excluded. The primary aminoglycoside. However, several outcome was 30-day all-cause mortality.
    [Show full text]
  • The Peres Center for Peace, Tel-Aviv April 12Th, 2019
    April 12th, 2019 The Peres Center for Peace, Tel-Aviv BREAST CANCER INNOVATIONS The Israeli Society for Clinical Oncology and Radiation Therapy and Roche are Pleased to Invite You to an Enriching and Educating Meeting with our Distinguished Guest Speaker: Prof. Charles E. Geyer Please Send the Attached Registration Form to A.M Knasim No Later than April 1st 2019 E-mail: [email protected] Tel: 03-6081520 Fax: 03-6081522 Prof. Charles E. Geyer Friday, 12th April 2019 • Professor of Medicine 08:00-09:00 Welcome Reception • Harrigan, Haw, Luck Families Chair in Cancer Research 09:00-09:10 Opening Remarks • Virginia Commonwealth University, Massey Dr. Noa Efrat Ben-Baruch Cancer Center Head, Israeli Breast Cancer Group • Associate Director of Clinical Research Head, Department of Oncology Kaplan Medical Center Charles E. Geyer, Jr. is Professor of Medicine and the Harrigan, Haw, Luck Families Chair in Cancer Research at Virginia Commonwealth University Massey Chairmen: Dr. Georgeta Fried Cancer Center, an NCI-designated Cancer Center. He serves as Associate Director Head Breast Cancer Unit of Clinical Research for the Massey Cancer Center with oversight responsibility Rambam Medical Center for all cancer-related clinical research activities within the Center. Prof. Geyer Dr. Margarita Tokar has devoted most of his academic career on the design and conduct of multi- institutional, phase III clinical trials in breast cancer with a particular focus on Senior Oncologist the development of HER2 targeted therapies. He has served in several leadership Soroka University Medical Center positions for multi-institution research initiatives. These include vice-chair of the 09:10-09:30 Personalized Nanothechnologies in the National Surgical Adjuvant Breast and Bowel Project (NSABP) Breast Committee Management of Breast Cancer from 1999 until 2007, Associate Director of Medical Affairs from 2002 to 2006 and Director of Medical Affairs for NSABP from 2006 to 2011.
    [Show full text]
  • December 2013 Prof. Reuven Zimlichman Chief of Medicine and Hypertension Institute, the E
    R. Zimlichman M.D. December 2013 Prof. Reuven Zimlichman Chief of Medicine and Hypertension Institute, The E. Wolfson Medical Center P.O.B. 5, Holon 58100 Israel and Head of Cardiovascular Research Institute, Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel Phone: 972-3-5028614, FAX: 972-3- 5032693 e-mail: [email protected] Prof. R. Zimlichman, M.D. is presently Chief Departments of Medicine and Head of Hypertension Institute at the E. Wolfson Medical Center, Israel, he is the Director of The Brunner Cardiovascular Research Institute, Tel-Aviv University. He is also the immediate past Vice Dean and Head of School of Continuing Education, Sackler Faculty of Medicine, Tel Aviv University. Prof. Zimlichman did his fellowship in Hypertension at the Hypertension Endocrine Branch, NIH, NHLBI in Bethesda, Maryland, USA (1983 to 1986). During the following years he returned for prolonged periods of research in the Hypertension Endocrine Branch and in the Clinical Neurocardiology section. Prof. Zimlichman joined the Faculty of Health Sciences at Ben Gurion University and Soroka Medical Center in Beer Sheva, Israel. He was nominated as Chief of Clinical and Experimental Hypertension in the Faculty of Medicine and in the Medical Center. Prof. Zimlichman was nominated as Chief of Medicine in the Sheba Medical Center, Tel Hashomer, in 1989 and was nominated as Associate Professor in Medicine at the Tel Aviv University, Sackler School of Medicine in 1994. In 1991 Prof Zimlichman was nominated as Chief of Department of Medicine in the Wolfson Medical Center, and in 1998 was nominated as Chief Departments of Medicine at the Wolfson Medical Center.
    [Show full text]
  • APF Newsletter, Winter 2006 – 2007
    Winter 2006-2007 APF A Newsletter of the From The President AmericanEmergency Physicians andFellowship Disaster Preparednessfor Medicine in Israel Course News in Israel From The President Israel in Crisis Mission August 2006 would like to share with our members and donors the important by Dr. Dan Moskowitz I APF activities of the past 6 months. his past August, I had the privilege of being invited to par- 1. APF ISRAEL CRISIS FUND REPORT After placing on our T ticipate in an Emergency APF Mission to Israel with APF website and sending a special crisis appeal from Dr. Danny Laor, Board members Drs. Mike Frogel, Paul Liebman and Charles the Deputy Minister for Emergency Preparedness, on the critical Kurtzer. Dr. Boaz Tadmor organized an incredible, whirlwind needs of the Northern hospitals, it was very gratifying indeed that over $100,000 tour for us, only two days after the cessation of hostilities in was received for our Crisis Fund. All of this will be distributed to hospitals such as Israel. We were provided with a unique glimpse of the Israeli Sieff Hospital in Safed, Poriya in Tiberias, Western Galilee Medical Center in Nahariya, and Rambam Medical Center in Haifa, with the hospital CEO’s given the healthcare system under stress, including face-to-face meet- discretion as to how best to utilize these funds to help their hospital in light of the ings with top healthcare officials, as well as visits to the trau- recent crisis. matized hospitals in northern Israel. Perhaps most importantly, we visited 2. MISSION TO ISRAEL Three APF Board members, Drs.
    [Show full text]
  • ERJ-02682-2020.Shareable
    ORIGINAL ARTICLE | LUNG CANCER Validation of Lung EpiCheck, a novel methylation-based blood assay, for the detection of lung cancer in European and Chinese high-risk individuals Mina Gaga 1, Joanna Chorostowska-Wynimko 2, Ildikó Horváth3, Martin C. Tammemagi4, David Shitrit5, Vered H. Eisenberg6, Hao Liang7, David Stav8, Dan Levy Faber9,10, Maarten Jansen11, Yael Raviv12, Vasileios Panagoulias13, Piotr Rudzinski2, Gabriel Izbicki14, Ohad Ronen 15, Adiv Goldhaber 16, Rawia Moalem17, Nadir Arber18, Ilana Haas19 and Qinghua Zhou 7 Affiliations: 17th Respiratory Medicine Dept, Athens Chest Hospital, Athens, Greece. 2National Institute of Tuberculosis and Lung Diseases, Warsaw, Poland. 3National Korányi Institute of Pulmonology, Budapest, Hungary. 4Brock University, St Catharines, ON, Canada. 5Pulmonary Dept, Meir Medical Center, Kfar Saba, Israel. 6Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. 7Lung Cancer Center/Lung Cancer Institute, West China Hospital, Sichuan University, Chengdu, China. 8Lung Institute, Maccabi Health Services Hashalom, Tel-Aviv, Israel. 9Dept of Cardiothoracic Surgery, Lady Davis Carmel Medical Center, Haifa, Israel. 10Ruth and Bruce Rappaport Faculty of Medicine, Technion – Israel Institute of Technology, Haifa, Israel. 11Pulmonary Dept, Ziekenhuisgroep Twente, Hengelo, The Netherlands. 12Dept of Medicine, Pulmonology Institute, Soroka Medical Center, Ben-Gurion University, Beer-Sheva, Israel. 132nd Respiratory Medicine Dept, Athens Chest Hospital, Athens, Greece. 14Pulmonary Institute, Shaare Zedek Medical Center, Jerusalem, Israel. 15Dept of Otolaryngology – Head and Neck Surgery, Galilee Medical Center affiliated with Azrieli Faculty of Medicine, Safed, Israel. 16Clalit Health Services, Raanana, Israel. 17Gastroenterology Institute, The Holy Family Hospital, Nazareth, Israel. 18Integrated Cancer Prevention Center, Tel Aviv Sourasky Medical Centre, Sackler Faculty of Medicine, Tel Aviv University, Tel-Aviv, Israel.
    [Show full text]